| [1] |
Guo DA, Lu A, Liu L. 2012. Modernization of traditional Chinese medicine. |
| [2] |
Newman DJ, Cragg GM. 2020. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. |
| [3] |
Saldívar-González FI, Aldas-Bulos VD, Medina-Franco JL, Plisson F. 2022. Natural product drug discovery in the artificial intelligence era. |
| [4] |
Banihashemi ZS, Azizi-Fini I, Rajabi M, Maghami M, Yadollahi S. 2025. Chronic fatigue syndrome post-COVID-19: triple-blind randomised clinical trial of Astragalus root extract. |
| [5] |
Zhang R, Zhu X, Bai H, Ning K. 2019. Network pharmacology databases for traditional Chinese medicine: review and assessment. |
| [6] |
Wang Y, Liu B, Fu X, Tong T, Yu Z. 2021. Efficacy and safety of Si-Jun-Zi-Tang-based therapies for functional (non-ulcer) dyspepsia: a meta-analysis of randomized controlled trials. |
| [7] |
Wang X, Shi X, Xi Z, Zhang Z, Luo Z, et al. 2026. The scientific basis of synergy in traditional Chinese medicine: physicochemical, pharmacokinetic, and pharmacodynamic perspectives. |
| [8] |
Liu J, Wei LX, Wang Q, Lu YF, Zhang F, et al. 2018. A review of cinnabar (HgS) and/or realgar (As4S4)-containing traditional medicines. |
| [9] |
Huang C, Zhu Z, Cao X, Chen X, Fu Y, et al. 2017. A pectic polysaccharide from Sijunzi decoction promotes the antioxidant defenses of SW480 cells. |
| [10] |
Xu B, Li X, Hu S, Bao Y, Chen F, et al. 2022. Safety and efficacy of Yupingfeng granules in children with recurrent respiratory tract infection: a randomized clinical trial. |
| [11] |
Song T, Hou X, Yu X, Wang Z, Wang R, et al. 2016. Adjuvant treatment with yupingfeng formula for recurrent respiratory tract infections in children: a meta-analysis of randomized controlled trials. |
| [12] |
Xin S, Cheng X, Zhu B, Liao X, Yang F, et al. 2020. Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment. |
| [13] |
Liu S, Yao C, Xie J, Liu H, Wang H, et al. 2023. Effect of an herbal-based injection on 28-day mortality in patients with sepsis: the EXIT-SEP randomized clinical trial. |
| [14] |
Li X, Zhang J, Huang J, Ma A, Yang J, et al. 2013. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. |
| [15] |
Li S, Zhang B. 2013. Traditional Chinese medicine network pharmacology: theory, methodology and application. |
| [16] |
Qu J, Zhang T, Liu J, Su Y, Wang H. 2019. Considerations for the quality control of newly registered traditional Chinese medicine in China: a review. |
| [17] |
Newman DJ. 2019. The impact of decreasing biodiversity on novel drug discovery: is there a serious cause for concern? |
| [18] |
Ren YS, Li HL, Piao XH, Yang ZY, Wang SM, et al. 2021. Drug affinity responsive target stability (DARTS) accelerated small molecules target discovery: principles and application. |
| [19] |
Xu Y, Liu X, Cao X, Huang C, Liu E, et al. 2021. Artificial intelligence: a powerful paradigm for scientific research. |
| [20] |
Kaul V, Enslin S, Gross SA. 2020. History of artificial intelligence in medicine. |
| [21] |
Alakhdar A, Poczos B, Washburn N. 2024. Diffusion models in de novo drug design. |
| [22] |
Jiang J, Chen L, Ke L, Dou B, Zhang C, et al. 2025. A review of transformer models in drug discovery and beyond. |
| [23] |
He X, Sun M, Battulga T, Copp BR, Rustamovna DK, et al. 2025. Application of artificial intelligence in the development of traditional Chinese medicine. |
| [24] |
Chen W, Liu X, Zhang S, Chen S. 2023. Artificial intelligence for drug discovery: resources, methods, and applications. |
| [25] |
Graber D, Stockinger P, Meyer F, Mishra S, Horn C, et al. 2025. Resolving data bias improves generalization in binding affinity prediction. |
| [26] |
Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, et al. 2021. Artificial intelligence in drug discovery and development. |
| [27] |
Noor F, Asif M, Ashfaq UA, Qasim M, Tahir ul Qamar M. 2023. Machine learning for synergistic network pharmacology: a comprehensive overview. |
| [28] |
Liu P, Huang F, Zheng X, Hao H. 2025. Targetome-guided combination drug discovery as next-generation therapeutics. |
| [29] |
Mullowney MW, Duncan KR, Elsayed SS, Garg N, van der Hooft JJJ, et al. 2023. Artificial intelligence for natural product drug discovery. |
| [30] |
Li X, Li X, Wang L, Hou Y, Liu Y, et al. 2025. Advancing traditional Chinese medicine research through network pharmacology: strategies for target identification, mechanism elucidation and innovative therapeutic applications. |
| [31] |
Tian S, Zhang J, Yuan S, Wang Q, Lv C, et al. 2023. Exploring pharmacological active ingredients of traditional Chinese medicine by pharmacotranscriptomic map in ITCM. |
| [32] |
Yan D, Zheng G, Wang C, Chen Z, Mao T, et al. 2022. HIT 2.0: an enhanced platform for Herbal Ingredients' Targets. |
| [33] |
Knox C, Wilson M, Klinger CM, Franklin M, Oler E, et al. 2024. DrugBank 6.0: the DrugBank Knowledgebase for 2024. |
| [34] |
Liu Z, Cai C, Du J, Liu B, Cui L, et al. 2020. TCMIO: a comprehensive database of traditional Chinese medicine on immuno-oncology. |
| [35] |
Zhang Y, Li X, Shi Y, Chen T, Xu Z, et al. 2023. ETCM v2.0: an update with comprehensive resource and rich annotations for traditional Chinese medicine. |
| [36] |
Fang S, Dong L, Liu L, Guo J, Zhao L, et al. 2021. HERB: a high-throughput experiment- and reference-guided database of traditional Chinese medicine. |
| [37] |
Chen Q, Springer L, Gohlke BO, Goede A, Dunkel M, et al. 2021. SuperTCM: a biocultural database combining biological pathways and historical linguistic data of Chinese Materia Medica for drug development. |
| [38] |
Kim S, Chen J, Cheng T, Gindulyte A, He J, et al. 2019. PubChem 2019 update: improved access to chemical data. |
| [39] |
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, et al. 2024. The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. |
| [40] |
Liu T, Hwang L, Burley SK, Nitsche CI, Southan C, et al. 2025. BindingDB in 2024: a FAIR knowledgebase of protein-small molecule binding data. |
| [41] |
Avram S, Wilson TB, Curpan R, Halip L, Borota A, et al. 2023. DrugCentral 2023 extends human clinical data and integrates veterinary drugs. |
| [42] |
Siramshetty VB, Eckert OA, Gohlke BO, Goede A, Chen Q, et al. 2018. SuperDRUG2: a one stop resource for approved/marketed drugs. |
| [43] |
Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, et al. 2016. The GeneCards Suite: from gene data mining to disease genome sequence analyses. |
| [44] |
Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, et al. 2024. TTD: Therapeutic Target Database describing target druggability information. |
| [45] |
Piñero J, Ramírez-Anguita JM, Saüch-Pitarch J, Ronzano F, Centeno E, et al. 2020. The DisGeNET knowledge platform for disease genomics: 2019 update. |
| [46] |
Lv Q, Chen G, He H, Yang Z, Zhao L, et al. 2023. TCMBank: bridges between the largest herbal medicines, chemical ingredients, target proteins, and associated diseases with intelligence text mining. |
| [47] |
Gao K, Liu L, Lei S, Li Z, Huo P, et al. 2025. HERB 2.0: an updated database integrating clinical and experimental evidence for traditional Chinese medicine. |
| [48] |
Kim SK, Lee MK, Jang H, Lee JJ, Lee S, et al. 2024. TM-MC 2.0: an enhanced chemical database of medicinal materials in Northeast Asian traditional medicine. |
| [49] |
Yang P, Lang J, Li H, Lu J, Lin H, et al. 2022. TCM-Suite: a comprehensive and holistic platform for Traditional Chinese Medicine component identification and network pharmacology analysis. |
| [50] |
Liu X, Liu J, Fu B, Chen R, Jiang J, et al. 2023. DCABM-TCM: a database of constituents absorbed into the blood and metabolites of traditional Chinese medicine. |
| [51] |
Zhang LX, Dong J, Wei H, Shi SH, Lu AP, et al. 2022. TCMSID: a simplified integrated database for drug discovery from traditional chinese medicine. |
| [52] |
Wu Y, Zhang F, Yang K, Fang S, Bu D, et al. 2019. SymMap: an integrative database of traditional Chinese medicine enhanced by symptom mapping. |
| [53] |
Huang L, Xie D, Yu Y, Liu H, Shi Y, et al. 2018. TCMID 2. 0: a comprehensive resource for TCM. |
| [54] |
Li B, Ma C, Zhao X, Hu Z, Du T, et al. 2018. YaTCM: yet another traditional Chinese medicine database for drug discovery. |
| [55] |
Ru J, Li P, Wang J, Zhou W, Li B, et al. 2014. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. |
| [56] |
Yang D, Zhu Z, Yao Q, Chen C, Chen F, et al. 2023. ccTCM: a quantitative component and compound platform for promoting the research of traditional Chinese medicine. |
| [57] |
Wang Y, Xiao J, Suzek TO, Zhang J, Wang J, et al. 2009. PubChem: a public information system for analyzing bioactivities of small molecules. |
| [58] |
Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, et al. 2012. ChEMBL: a large-scale bioactivity database for drug discovery. |
| [59] |
Sun X, Wei Z, Yu X, Liu K, Yao S, et al. 2026. DRESIS 2.0: the comprehensive landscape of drug resistance information. |
| [60] |
Li F, Mou M, Li X, Xu W, Yin J, et al. 2025. DrugMAP 2.0: molecular atlas and pharma-information of all drugs. |
| [61] |
Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D. 1997. GeneCards: integrating information about genes, proteins and diseases. |
| [62] |
Kong X, Liu C, Zhang Z, Cheng M, Mei Z, et al. 2024. BATMAN-TCM 2.0: an enhanced integrative database for known and predicted interactions between traditional Chinese medicine ingredients and target proteins. |
| [63] |
Lin H, Hou D, Jiang X, Yin R, Yu S, et al. 2026. NPASS database update 2026: comprehensive quantitative composition, bioactivity, and ADME-Tox data of natural products for biomedical research. |
| [64] |
Lv Q, Chen G, He H, Yang Z, Zhao L, et al. 2023. TCMBank-the largest TCM database provides deep learning-based Chinese-Western medicine exclusion prediction. |
| [65] |
Willett P. 2006. Similarity-based virtual screening using 2D fingerprints. |
| [66] |
Rogers D, Hahn M. 2010. Extended-connectivity fingerprints. |
| [67] |
Duvenaud DK, Maclaurin D, Aguilera-Iparraguirre J, Gómez-Bombarelli R, Hirzel T, et al. 2015. Convolutional networks on graphs for learning molecular fingerprints. NIPS'15: Proceedings of the 29th International Conference on Neural Information Processing Systems, December 7−12, 2015, Montreal, Canada. Vol. 2. Cambridge, United States: MIT Press. pp. 2224−2232 https://dl.acm.org/doi/proceedings/10.5555/2969442 |
| [68] |
Yang K, Swanson K, Jin W, Coley C, Eiden P, et al. 2019. Analyzing learned molecular representations for property prediction. |
| [69] |
Del Prete E, Facchiano A, Liò P. 2020. Bioinformatics methodologies for coeliac disease and its comorbidities. |
| [70] |
Lin Y, Zhang Y, Wang D, Yang B, Shen YQ. 2022. Computer especially AI-assisted drug virtual screening and design in traditional Chinese medicine. |
| [71] |
Ma J, Sheridan RP, Liaw A, Dahl GE, Svetnik V. 2015. Deep neural nets as a method for quantitative structure-activity relationships. |
| [72] |
Arora B, Coudrat T, Wootten D, Christopoulos A, Noronha SB, Sexton PM. 2016. Prediction of loops in G protein-coupled receptor homology models: effect of imprecise surroundings and constraints. |
| [73] |
Wu Z, Ramsundar B, Feinberg EN, Gomes J, Geniesse C, et al. 2018. MoleculeNet: a benchmark for molecular machine learning. |
| [74] |
Zhang S, Huo D, Horne RI, Qi Y, Pujalte Ojeda S, et al. 2025. Sequence-based virtual screening using transformers. |
| [75] |
López-Pérez K, López-López E, Medina-Franco JL, Miranda-Quintana RA. 2023. Sampling and mapping chemical space with extended similarity indices. |
| [76] |
Wu H, Liu J, Zhang R, Lu Y, Cui G, et al. 2024. A review of deep learning methods for ligand based drug virtual screening. |
| [77] |
Koirala M, Yan L, Mohamed Z, DiPaola M. 2025. AI-integrated QSAR modeling for enhanced drug discovery: from classical approaches to deep learning and structural insight. |
| [78] |
Kattuparambil AA, Chaurasia DK, Shekhar S, Srinivasan A, Mondal S, et al. 2025. Exploring chemical space for "druglike" small molecules in the age of AI. |
| [79] |
Xie S, Zhu H, Huang N. 2025. AI-designed molecules in drug discovery, structural novelty evaluation, and implications. |
| [80] |
Pathan I, Raza A, Sahu A, Joshi M, Sahu Y, et al. 2025. Revolutionizing pharmacology: AI-powered approaches in molecular modeling and ADMET prediction. |
| [81] |
Niazi SK. 2025. Artificial Intelligence in Small-molecule drug discovery: a critical review of methods, applications, and real-world outcomes. |
| [82] |
Sim J, Kim D, Kim B, Choi J, Lee J. 2025. Recent advances in AI-driven protein-ligand interaction predictions. |
| [83] |
Zhou G, Rusnac DV, Park H, Canzani D, Nguyen HM, et al. 2024. An artificial intelligence accelerated virtual screening platform for drug discovery. |
| [84] |
Rashid MA, Radhika NM, Yogeeta OA, Sameer NG, Kartik TN, et al. 2025. Recent advances in molecular docking techniques: transforming perspectives in distinct drug targeting and drug discovery approaches. |
| [85] |
Zhang Z, Quan L, Wang J, Peng L, Chen Q, et al. 2025. LABind: identifying protein binding ligand-aware sites via learning interactions between ligand and protein. |
| [86] |
Yang Z, Ji J, He S, Li J, He T, et al. 2024. Dockformer: A transformer-based molecular docking paradigm for large-scale virtual screening. |
| [87] |
Sharma G, Kumar N, Sharma CS, Alqahtani T, Tiruneh YK, et al. 2025. Identification of promising SARS-CoV-2 main protease inhibitor through molecular docking, dynamics simulation, and ADMET analysis. |
| [88] |
Hasan GM, Mohammad T, Zaidi S, Shamsi A, Hassan MI. 2025. Molecular docking and dynamics in protein serine/threonine kinase drug discovery: advances, challenges, and future perspectives. |
| [89] |
Wang Y, Li Y, Chen J, Lai L. 2025. Modeling protein-ligand interactions for drug discovery in the era of deep learning. |
| [90] |
Wang S, Zhang L, Zhang W, Zeng X, Mei J, et al. 2025. Structure-based molecular screening and dynamic simulation of phytocompounds targeting VEGFR-2: a novel therapeutic approach for papillary thyroid carcinoma. |
| [91] |
Li D, Hu J, Zhang L, Li L, Yin Q, et al. 2022. Deep learning and machine intelligence: new computational modeling techniques for discovery of the combination rules and pharmacodynamic characteristics of Traditional Chinese Medicine. |
| [92] |
Abramson J, Adler J, Dunger J, Evans R, Green T, et al. 2024. Accurate structure prediction of biomolecular interactions with AlphaFold 3. |
| [93] |
Takaba K, Friedman AJ, Cavender CE, Behara PK, Pulido I, et al. 2024. Machine-learned molecular mechanics force fields from large-scale quantum chemical data. |
| [94] |
Hopkins AL. 2008. Network pharmacology: the next paradigm in drug discovery. |
| [95] |
Cui G, Li M, Guo W, Gao M, Zhu Q, et al. 2025. AI driven network pharmacology: multi-scale mechanisms of traditional Chinese medicine from molecular to patient analysis. |
| [96] |
Jiang W, Ye W, Tan X, Bao YJ. 2025. Network-based multi-omics integrative analysis methods in drug discovery: a systematic review. |
| [97] |
Picard M, Scott-Boyer MP, Bodein A, Périn O, Droit A. 2021. Integration strategies of multi-omics data for machine learning analysis. |
| [98] |
Wei S, Sasi C, Piepenbrock J, Huynen MA, t Hoen PAC. 2025. The use of knowledge graphs for drug repurposing: from classical machine learning algorithms to graph neural networks. |
| [99] |
Ying H, Kong W, Xu X. 2025. Integrated network pharmacology, machine learning and experimental validation to identify the key targets and compounds of TiaoShenGongJian for the treatment of breast cancer. |
| [100] |
Ding C, Liao Q, Zuo R, Zhang S, Guo Z, et al. 2024. Machine learning potential predictor of idiopathic pulmonary fibrosis. |
| [101] |
Zhao H, He L, Yin D, Song B. 2019. Identification of β-catenin target genes in colorectal cancer by interrogating gene fitness screening data. |
| [102] |
LeCun Y, Bengio Y, Hinton G. 2015. Deep learning. |
| [103] |
Chen H, King FJ, Zhou B, Wang Y, Canedy CJ, et al. 2024. Drug target prediction through deep learning functional representation of gene signatures. |
| [104] |
Qu Z, Wang W, Hou C, Hou C. 2019. Radar signal intra-pulse modulation recognition based on convolutional denoising autoencoder and deep convolutional neural network. |
| [105] |
Zhang S, Zhang X, Du J, Wang W, Pi X. 2024. Multi-target meridians classification based on the topological structure of anti-cancer phytochemicals using deep learning. |
| [106] |
Zhang Z, Chen L, Zhong F, Wang D, Jiang J, et al. 2022. Graph neural network approaches for drug-target interactions. |
| [107] |
Guo X, Zhao X, Lu X, Zhao L, Zeng Q, et al. 2024. A deep learning-driven discovery of berberine derivatives as novel antibacterial against multidrug-resistant Helicobacter pylori. |
| [108] |
Duan YJ, Fu L, Zhang XC, Long TZ, He YH, et al. 2023. Improved GNNs for log D(7.4) prediction by transferring knowledge from low-fidelity data. |
| [109] |
Kimber TB, Chen Y, Volkamer A. 2021. Deep learning in virtual screening: recent applications and developments. |
| [110] |
Zakharov AV, Peach ML, Sitzmann M, Nicklaus MC. 2014. QSAR modeling of imbalanced high-throughput screening data in PubChem. |
| [111] |
Huang S, Zhang L, Liu X. 2025. Bioinformatics approach to identifying molecular targets of isoliquiritigenin affecting chronic obstructive pulmonary disease: a machine learning pharmacology study. |
| [112] |
Lu X, Xie L, Xu L, Mao R, Xu X, et al. 2024. Multimodal fused deep learning for drug property prediction: integrating chemical language and molecular graph. |
| [113] |
MacLean F. 2021. Knowledge graphs and their applications in drug discovery. |
| [114] |
Yu Z, Li T, Zheng Z, Yang X, Guo X, et al. 2025. Tailoring a traditional Chinese medicine prescription for complex diseases: a novel multi-targets-directed gradient weighting strategy. |
| [115] |
Zhang J, Li H, Zhang Y, Huang J, Ren L, et al. 2025. Computational toxicology in drug discovery: applications of artificial intelligence in ADMET and toxicity prediction. |
| [116] |
Wu C, Wu C, Peng L, Wu M, Li Z, et al. 2024. Multi-omics approaches for the understanding of therapeutic mechanism for Huang-Qi-Long-Dan Granule against ischemic stroke. |
| [117] |
Khanal S, Kumar A, Kumar P, Thakur P, Chander AM, et al. 2025. Unraveling bioactive potential and production in Ganoderma lucidum through omics and machine learning modeling. |
| [118] |
Mohammadi-Shemirani P, Sood T, Paré G. 2023. From 'omics to multi-omics technologies: the discovery of novel causal mediators. |
| [119] |
Chen LG, Tubbs JD, Liu Z, Thach TQ, Sham PC. 2024. Mendelian randomization: causal inference leveraging genetic data. |
| [120] |
Li Y, Miao Y, Feng Q, Zhu W, Chen Y, et al. 2024. Mitochondrial dysfunction and onset of type 2 diabetes along with its complications: a multi-omics Mendelian randomization and colocalization study. |
| [121] |
Huang L, Liu J, Zheng X, Zhang K, Chen Y, et al. 2026. Integrated multi-omics mapping of the causal landscape of gout across the circulating-tissue axis. |
| [122] |
Garcia-Argibay M, Wootton RE, Larsson H, Mattheisen M, Polimanti R, et al. 2026. Causal inference in psychiatric research: how to critically evaluate and interpret mendelian randomization studies. |
| [123] |
Yazdani A, Yazdani A, Mendez-Giraldez R, Samiei A, Kosorok MR, et al. 2022. From classical mendelian randomization to causal networks for systematic integration of multi-omics. |
| [124] |
Yang J, Yang H, Wang F, Dai Y, Deng Y, et al. 2025. Bioinformatics identification based on causal association inference using multi-omics reveals the underlying mechanism of Gui-Zhi-Shao-Yao-Zhi-Mu decoction in modulating rheumatoid arthritis. |
| [125] |
Schölkopf B, Locatello F, Bauer S, Ke NR, Kalchbrenner N, et al. 2021. Toward causal representation learning. |
| [126] |
Dixit A, Parnas O, Li B, Chen J, Fulco CP, et al. 2016. Perturb-Seq: dissecting molecular circuits with scalable single-cell RNA profiling of pooled genetic screens. |
| [127] |
Subramanian I, Verma S, Kumar S, Jere A, Anamika K. 2020. Multi-omics data integration, interpretation, and its application. |
| [128] |
Hasin Y, Seldin M, Lusis A. 2017. Multi-omics approaches to disease. |
| [129] |
Shataer D, Cao S, Liu X, Aierken K, Bhattacharya P, et al. 2025. Application of large language models in traditional Chinese medicine: a state-of-the-art review. |
| [130] |
Guo P, Jiang M, Hu S, Jiang Q, Li L, et al. 2026. Advancing the modernization of traditional Chinese medicine through artificial intelligence and multimodal data integration. |
| [131] |
Hogan A, Blomqvist E, Cochez M, D'amato C, De Melo G, et al. 2021. Knowledge graphs. |
| [132] |
Han C, Yang G, Li H, Zhu L, Feng M. 2026. Tuning and clinical application of large language models in Traditional Chinese Medicine: scoping review. |
| [133] |
Wang L, Tang K, Wang Y, Zhang P, Li S. 2025. Advancements in Artificial intelligence-driven diagnostic models for traditional Chinese medicine. |
| [134] |
Dai Y, Shao X, Zhang J, Chen Y, Chen Q, et al. 2024. TCMChat: A generative large language model for traditional Chinese medicine. |
| [135] |
Liu Z, Yang T, Wang J, Chen Y, Gao Z, et al. 2026. Tianyi: a traditional Chinese medicine all-rounder language model and its real-world clinical practice. |
| [136] |
Chen Y, Wang Z, Xing X, Zheng H, Xu Z, et al. 2023. BianQue: balancing the questioning and suggestion ability of health LLMs with multi-turn health conversations polished by ChatGPT. |
| [137] |
Zhou W, Gao Y. 2026. Phenotype-target coupled drug screening: a high-efficiency framework for innovative drug discovery from CHMs. |
| [138] |
Li Y, Liu X, Zhou J, Li F, Wang Y, et al. 2025. Artificial intelligence in traditional Chinese medicine: advances in multi-metabolite multi-target interaction modeling. |
| [139] |
Bittner MI, Farajnia S. 2022. AI in drug discovery: applications, opportunities, and challenges. |
| [140] |
Bastos M, Abian O, Johnson CM, Ferreira-da-Silva F, Vega S, et al. 2023. Isothermal titration calorimetry. |
| [141] |
Li L, Zhang J, Li Y, Huang C, Xu J, et al. 2024. Dielectric surface-based biosensors for enhanced detection of biomolecular interactions: advances and applications. |
| [142] |
Hong M, Du Y, Chen D, Shi Y, Hu M, et al. 2023. Martynoside rescues 5-fluorouracil-impaired ribosome biogenesis by stabilizing RPL27A. |
| [143] |
Baell JB, Holloway GA. 2010. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. |
| [144] |
McGovern SL, Caselli E, Grigorieff N, Shoichet BK. 2002. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. |
| [145] |
Leelananda SP, Lindert S. 2016. Computational methods in drug discovery. |
| [146] |
Chen X, Wang Y, Ma N, Tian J, Shao Y, et al. 2020. Target identification of natural medicine with chemical proteomics approach: probe synthesis, target fishing and protein identification. |
| [147] |
Wang S, Zhang Y, Yu R, Chai Y, Liu R, et al. 2024. Labeled and label-free target identifications of natural products. |
| [148] |
Wang Q, Du T, Zhang Z, Zhang Q, Zhang J, et al. 2024. Target fishing and mechanistic insights of the natural anticancer drug candidate chlorogenic acid. |
| [149] |
Parker CG, Pratt MR. 2020. Click chemistry in proteomic investigations. |
| [150] |
Schenone M, Dančík V, Wagner BK, Clemons PA. 2013. Target identification and mechanism of action in chemical biology and drug discovery. |
| [151] |
Martinez Molina D, Jafari R, Ignatushchenko M, Seki T, Larsson EA, et al. 2013. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. |
| [152] |
Savitski MM, Reinhard FB, Franken H, Werner T, Savitski MF, et al. 2014. Tracking cancer drugs in living cells by thermal profiling of the proteome. |
| [153] |
Lomenick B, Hao R, Jonai N, Chin RM, Aghajan M, et al. 2009. Target identification using drug affinity responsive target stability (DARTS). |
| [154] |
Yu R, Zhang ZQ, Wang B, Jiang HX, Cheng L, et al. 2014. Berberine-induced apoptotic and autophagic death of HepG2 cells requires AMPK activation. |
| [155] |
Lin A, Giuliano CJ, Palladino A, John KM, Abramowicz C, et al. 2019. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. |
| [156] |
Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, et al. 2014. Genome-scale CRISPR-Cas9 knockout screening in human cells. |
| [157] |
Tian S, Qin Y, Wu Y, Dong M. 2025. Design, performance, processing, and validation of a pooled CRISPR perturbation screen for bacterial toxins. |
| [158] |
Jansson-Löfmark R, Fridén M, Badolo L, Ahlström C, Gurrell I, et al. 2025. Translational PK/PD: a retrospective analysis of performance and impact from a drug portfolio. |
| [159] |
Haid RTU, Reichel A. 2025. PK/PD modeling of targeted protein degraders: charting new waters and navigating the shallows. |
| [160] |
Sun Q, Tu K, Xu Q, Yan L, Yang S, et al. 2025. Berberine suppresses colorectal cancer progression by inducing ferroptosis-mediated energy metabolism disorders. |
| [161] |
Sweis RF. 2015. Target (In)Validation: a critical, sometimes unheralded, role of modern medicinal chemistry. |
| [162] |
Qi H, Chen S, Chen X, Ma Q, Shi J, et al. 2025. Multi-dimensional PK-PD insights into Lianhua Qingwen's formula compatibility. |
| [163] |
Topol EJ. 2019. High-performance medicine: the convergence of human and artificial intelligence. |
| [164] |
Waman VP, Sen N, Varadi M, Daina A, Wodak SJ, et al. 2021. The impact of structural bioinformatics tools and resources on SARS-CoV-2 research and therapeutic strategies. |
| [165] |
Patchipala S. 2023. Tackling data and model drift in AI: strategies for maintaining accuracy during ML model inference. |
| [166] |
Huang K, Chandak P, Wang Q, Havaldar S, Vaid A, et al. 2024. A foundation model for clinician-centered drug repurposing. |
| [167] |
Guo XX, An S, Bao F, Xu TR. 2023. Challenges and perspectives in target identification and mechanism illustration for Chinese medicine. |
| [168] |
Jumper J, Evans R, Pritzel A, Green T, Figurnov M, et al. 2021. Highly accurate protein structure prediction with AlphaFold. |
| [169] |
Zhang P, Zhang D, Zhou W, Wang L, Wang B, et al. 2023. Network pharmacology: towards the artificial intelligence-based precision traditional Chinese medicine. |
| [170] |
Kauffmann J, Dippel J, Ruff L, Samek W, Müller KR, et al. 2025. Explainable AI reveals Clever Hans effects in unsupervised learning models. |
| [171] |
Tong X, Wang D, Ding X, Tan X, Ren Q, et al. 2022. Blood-brain barrier penetration prediction enhanced by uncertainty estimation. |
| [172] |
Vatansever S, Schlessinger A, Wacker D, Kaniskan H, Jin J, et al. 2021. Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: state-of-the-arts and future directions. |
| [173] |
Xu H, Zhao H, Ding C, Jiang D, Zhao Z, et al. 2023. Celastrol suppresses colorectal cancer via covalent targeting peroxiredoxin 1. |
| [174] |
Begley CG, Ellis LM. 2012. Drug development: raise standards for preclinical cancer research. |
| [175] |
Clevers H. 2016. Modeling development and disease with organoids. |
| [176] |
Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández-Mateos J, et al. 2018. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. |